HROW saw its Momentum Indicator move above the 0 level on November 13, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In 68 of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HROW's RSI Indicator exited the oversold zone, 29 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 56 cases where HROW's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for HROW just turned positive on October 20, 2026. Looking at past instances where HROW's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
HROW moved above its 50-day moving average on November 18, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in 236 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
HROW broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HROW entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. HROW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HROW's P/B Ratio (66.319) is slightly higher than the industry average of (6.379). P/E Ratio (-27.162) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (183.387).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The RSI Indicator for RDY moved into overbought territory on November 18, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 53 cases where RDY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for RDY turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 28 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
RDY broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RDY as a result. In 50 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
Following a +1.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where RDY advanced for three days, in 160 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 89 of 247 cases where RDY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 36%.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. RDY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.032) is normal, around the industry mean (6.379). P/E Ratio (0.375) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (1.666) is also within normal values, averaging (2.202). Dividend Yield (0.020) settles around the average of (0.062) among similar stocks. P/S Ratio (2.817) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 53 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 73 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
HROW | RDY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 90 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 59 | 53 | |
SMR RATING 1..100 | 99 | 73 | |
PRICE GROWTH RATING 1..100 | 61 | 39 | |
P/E GROWTH RATING 1..100 | 13 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 41 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RDY's Valuation (50) in the Pharmaceuticals Generic industry is somewhat better than the same rating for HROW (85) in the Pharmaceuticals Other industry. This means that RDY’s stock grew somewhat faster than HROW’s over the last 12 months.
RDY's Profit vs Risk Rating (53) in the Pharmaceuticals Generic industry is in the same range as HROW (59) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to HROW’s over the last 12 months.
RDY's SMR Rating (73) in the Pharmaceuticals Generic industry is in the same range as HROW (99) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to HROW’s over the last 12 months.
RDY's Price Growth Rating (39) in the Pharmaceuticals Generic industry is in the same range as HROW (61) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to HROW’s over the last 12 months.
HROW's P/E Growth Rating (13) in the Pharmaceuticals Other industry is significantly better than the same rating for RDY (97) in the Pharmaceuticals Generic industry. This means that HROW’s stock grew significantly faster than RDY’s over the last 12 months.
| HROW | RDY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 73% | 1 day ago 58% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 53% |
| Momentum ODDS (%) | 1 day ago 84% | 6 days ago 60% |
| MACD ODDS (%) | 1 day ago 78% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 50% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 46% |
| Advances ODDS (%) | 1 day ago 82% | 1 day ago 50% |
| Declines ODDS (%) | 7 days ago 80% | 7 days ago 55% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 46% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 36% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HROW’s FA Score shows that 1 FA rating(s) are green while RDY’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HROW’s TA Score shows that 6 TA indicator(s) are bullish while RDY’s TA Score has 3 bullish TA indicator(s).
HROW (@Pharmaceuticals: Generic) experienced а -2.77% price change this week, while RDY (@Pharmaceuticals: Generic) price change was -0.47% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.75%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -8.43%.
HROW is expected to report earnings on Mar 08, 2027.
RDY is expected to report earnings on Jan 22, 2027.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AQST. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AQST could also see price increases.
| Ticker / NAME | Correlation To HROW | 1D Price Change % | ||
|---|---|---|---|---|
| HROW | 100% | +8.94% | ||
| AQST - HROW | 35% Loosely correlated | +2.16% | ||
| AMRX - HROW | 31% Poorly correlated | +3.60% | ||
| RMTI - HROW | 27% Poorly correlated | -7.72% | ||
| TEVA - HROW | 27% Poorly correlated | -0.92% | ||
| SIGA - HROW | 26% Poorly correlated | +2.56% | ||
More | ||||
A.I.dvisor tells us that RDY and VTRS have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and VTRS's prices will move in lockstep.
| Ticker / NAME | Correlation To RDY | 1D Price Change % | ||
|---|---|---|---|---|
| RDY | 100% | +1.28% | ||
| VTRS - RDY | 28% Poorly correlated | -0.83% | ||
| ALKS - RDY | 28% Poorly correlated | +3.08% | ||
| TEVA - RDY | 27% Poorly correlated | -0.92% | ||
| HROW - RDY | 26% Poorly correlated | +8.94% | ||
| DERM - RDY | 25% Poorly correlated | -5.38% | ||
More | ||||